분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2011-09-02 01:47:38 , Hit : 2444
 Engineered Viruses Selectively Kill Cancer Cells

The experimental therapy could ultimately serve as a seek-and-destroy treatment for metastatic cancer.

Wednesday, August 31, 2011
By Alla Katsnelson

A single injection of a virus that has been genetically engineered to kill cancer cells can reliably infect tumors and leave healthy tissue unharmed, according to an early stage trial of 23 patients with metastatic cancers. The findings help lay the groundwork for a new type of cancer medicine using cancer-killing viruses.

Researchers injected different doses of the virus into patients with different types of metastatic cancers. After eight to 10 days, they biopsied tumor tissue from each patient and found that the virus was replicating itself in the tumors of seven of the eight patients who had received the highest dose, with no serious side effects. Several weeks after the injection, tumors in about half of the patients seemed to stop growing, and shrunk in one patient. The study is published today in the journal Nature.

While the study is not the first to test a cancer-killing viral therapy, it is the first to thoroughly document the behavior of the virus in patients' biopsy tissue. The results confirm that viruses can be used to selectively target these cells.  

One reason tumors can grow unchecked is that they suppress the immune system. However, this also makes tumor cells more susceptible to viruses, which replicate inside the infected cell until it bursts. Physicians have known for more than a century that viral infection slows tumor growth, and in recent years they've used molecular biology techniques to reëngineer more effective cancer-killing viruses.

Most such viruses now in trials are injected directly into the tumor. But what researchers really need is a therapy that could be injected into the bloodstream and seek out metastasized cancer cells throughout the body, says David Kirn, chief executive officer at Jennerex, the San Francisco-based biotech company that funded the study.

To develop JX-594, the therapy in the new study, researchers at Jennerex started with a strain of vaccinia virus, which is adept at evading the immune system. (It was also used in the smallpox vaccine.) They then armed it with a gene encoding a protein called GM-CSF, which triggers an immune attack against cancer cells. They also added a second gene for beta-galactosidase, a marker protein with which they could track the virus's replication.

The effect, says Kirn, was "a product that destroys tumors by multiple, complementary mechanisms."

Researchers still don't know how well the virus will combat cancer. Such early trials "are not supposed to determine efficacy, but obviously, everyone is looking," says Samuel Rabkin, a virologist at Massachusetts General Hospital in Boston. Rabkin was not involved in the study. Patients whose cancers seemed to stabilize weren't necessarily the ones in which the researchers found the virus replicating, he notes. "It is actually one of the large questions in the field—is the therapeutic effect directly related to the amount of virus replication in the tumor?"

Another concern is that if patients get more than one dose, the body might get better at fighting off the virus, which could disarm the therapy, says Nori Kasahara, a gene therapy researcher at the University of California, Los Angeles. "We just don't know how long-lasting the therapeutic benefit will be," he says. "If the immune system fights off the virus, then the tumor might just come back." Kasahara also did not participate in the research.

Jennerex is already testing the therapy in larger trials. It recently completed a trial in liver cancer that significantly improved patients' survival rates, Kirn says.

The current trial's results don't just bode well for JX-594, he says, but for the field of cancer-killing viruses overall. "We can now engineer a variety of different therapeutic products into this viral backbone."








1107   Dynamic view of the MS genome  이성욱 2010/05/01 2717
1106   Early-Earth cells modeled to show how first life forms might have packaged RNA  이성욱 2012/10/16 2515
1105   Editas Expands CRISPR Capabilities through New Technology Licensing  이성욱 2016/12/22 820
1104   Efficient Process Using microRNA Converts Human Skin Cells Into Neurons  이성욱 2011/07/19 2238
1103   Electronics Giant Samsung Makes First Big Biotech Play  이성욱 2013/02/22 3165
1102   EMA panel recommends approval of DAA regimen for patients with HCV  이성욱 2014/11/26 1283
1101   Embryonic stem cells improve vision for two women  이성욱 2012/01/25 2336
1100   Engineered Human Liver Tissue Grows in Mice  이성욱 2017/07/25 781
  Engineered Viruses Selectively Kill Cancer Cells  이성욱 2011/09/02 2444
1098   Engineering Better Immune Cells  이성욱 2010/05/06 2700
1097   EU, 2번째 유전자치료제 ‘스트림벨리스’ 승인  이성욱 2016/09/05 1147
1096   European regulators back first gene therapy drug  이성욱 2012/07/24 2669
1095   Exosomes Linked to Cancer Spread from Chemoresistant Tumors in Mice  이성욱 2019/01/15 779
1094   Expanding the reach of gene editing with a new CRISPR enzyme  이성욱 2018/10/26 399
1093   Experimental Hepatitis C Drug Shows Promise for Preventing Recurrence in Liver Transplant Patients  이성욱 2013/11/06 2134
1092   Experts find rogue stem cells in liver cancer  이성욱 2011/07/09 2570
1091   Fathers Can Pass Mitochondrial DNA to Children  이성욱 2018/12/26 796
1090   FDA approves 9-valent HPV vaccine for certain cancers  이성욱 2014/12/12 1142
1089   FDA Approves First Gene Therapy for Inherited Disease  이성욱 2017/12/22 512
1088   FDA Approves Gilead CAR-T Therapy Yescarta, Plans Regenerative Medicine Policy 'Soon'  이성욱 2017/10/20 608

[1][2][3][4][5][6][7][8] 9 [10]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN